Reni Benjamin
Stock Analyst at Citizens
(1.33)
# 3,584
Out of 5,050 analysts
173
Total ratings
36.81%
Success rate
-15.11%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $6.44 | +86.34% | 15 | Oct 31, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Market Perform | n/a | $1.18 | - | 8 | Aug 4, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $80.69 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.70 | +185.23% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.69 | +45.65% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $105.98 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.64 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.15 | +247.83% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.62 | +146.91% | 1 | Aug 8, 2022 | |
| ADVM Adverum Biotechnologies | Upgrades: Market Perform | n/a | $4.32 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.22 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.01 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $14.52 | -31.13% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $4.09 | +22.25% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $9.86 | +183.98% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $15.09 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $18.18 | +120.02% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.61 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.30 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.19 | +236.13% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.82 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.86 | -18.86% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $47.48 | +26.37% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.10 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $225.17 | +39.89% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $91.99 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $263.77 | +0.47% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.23 | +301.89% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.46 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $11.21 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.37 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $32.24 | -62.78% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $23.24 | - | 1 | Nov 15, 2017 |
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $6.44
Upside: +86.34%
Allogene Therapeutics
Aug 4, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.18
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $80.69
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.70
Upside: +185.23%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.69
Upside: +45.65%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $105.98
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.64
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.15
Upside: +247.83%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.62
Upside: +146.91%
Adverum Biotechnologies
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $4.32
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.22
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $7.01
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $14.52
Upside: -31.13%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $4.09
Upside: +22.25%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $9.86
Upside: +183.98%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $15.09
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $18.18
Upside: +120.02%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.61
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.30
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.19
Upside: +236.13%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.82
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.86
Upside: -18.86%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $47.48
Upside: +26.37%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.10
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $225.17
Upside: +39.89%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $91.99
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $263.77
Upside: +0.47%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.23
Upside: +301.89%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.46
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $11.21
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.37
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $32.24
Upside: -62.78%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $23.24
Upside: -